Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina 27710, USA.
Am J Med. 2012 Jan;125(1 Suppl):S39-51. doi: 10.1016/j.amjmed.2011.10.010.
Outcomes of fungal infections in immunocompromised individuals depend on a complex interplay between host and pathogen factors, as well as treatment modalities. Problems occur when host responses to an infection are either too weak to effectively help eradicate the pathogen, or when they become too strong and are associated with host damage rather than protection. Immune reconstitution syndrome (IRS) can be generally defined as a restoration of host immunity in a previously immunosuppressed patient that becomes dysregulated and overly robust, resulting in host damage and sometimes death. IRS associated with opportunistic mycoses presents as new or worsening clinical symptoms or radiographic signs consistent with an inflammatory process that occur during receipt of an appropriate antifungal, and that cannot be explained by a newly acquired infection. Because there are currently no established tests or biomarkers for IRS, it can be difficult to distinguish from progression of the original infection, although culture and biomarkers for the fungal pathogen or infection are typically negative during diagnostic workup. IRS was originally characterized in human immunodeficiency virus-infected patients receiving antiretroviral therapy, but has subsequently been described in solid-organ transplant recipients, neutropenic patients, women in the postpartum period, and recipients of tumor necrosis factor-α inhibitor therapy. In each of these cases, recovery of the host's immunity during treatment of an initial infection results in a powerful proinflammatory environment that overshoots and leads to host damage. Optimal management of IRS has not been established at present, but often involves treatment with a corticosteroid or other anti-inflammatory compounds. This article uses a number of patient cases to explore the intricacies of diagnosing and managing a patient with IRS, as well as the other extreme, namely patients who are so immunocompromised without immune recovery that they essentially become breeding grounds for a wide range of opportunistic pathogens, often simultaneously.
免疫功能低下个体的真菌感染的结果取决于宿主和病原体因素以及治疗方式之间的复杂相互作用。当宿主对感染的反应要么过于微弱而无法有效帮助清除病原体,要么变得过于强烈并与宿主损伤而不是保护相关时,就会出现问题。免疫重建综合征(IRS)通常可以定义为先前免疫抑制患者的宿主免疫恢复,但变得失调和过于活跃,导致宿主损伤,有时甚至导致死亡。与机会性真菌感染相关的 IRS 表现为新的或恶化的临床症状或影像学征象,与接受适当抗真菌治疗期间发生的炎症过程一致,并且不能用新获得的感染来解释。由于目前没有用于 IRS 的既定测试或生物标志物,因此很难将其与原始感染的进展区分开来,尽管在诊断过程中,真菌病原体或感染的培养和生物标志物通常为阴性。IRS 最初在接受抗逆转录病毒治疗的人类免疫缺陷病毒感染患者中被描述,但随后在实体器官移植受者、中性粒细胞减少症患者、产后妇女和肿瘤坏死因子-α抑制剂治疗的患者中被描述。在这些情况下,初始感染治疗过程中宿主免疫的恢复导致了强大的促炎环境,这种环境过度活跃并导致宿主损伤。目前尚未确定 IRS 的最佳治疗方法,但通常涉及使用皮质类固醇或其他抗炎化合物进行治疗。本文使用了一些患者病例来探讨诊断和管理 IRS 患者的复杂性,以及另一个极端情况,即那些免疫功能低下而没有免疫恢复的患者,他们基本上成为了广泛的机会性病原体的滋生地,通常同时存在多种病原体。